Author of the publication

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group

, , , , , , , , , , , , , , , , , , , and . Blood, 92 (12): 4560–4567 (1998)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group, , , , , , , , , and 15 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, (1998)Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin, , , , , , and . British journal of haematology, 109 (2): 367–375 (2000)BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group, , , , , , , , , and 1 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 8 (2): 143–148 (1997)Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group, , , , , , , , , and 10 other author(s). Blood, 92 (12): 4560–4567 (1998)Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease, , , , , , , , , and 15 other author(s). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 (6): 2275–2287 (1997)Die Therapie des Morbus Hodgkin, , , , and . Der Internist, 39 (9): 917–926 (1998)Serum cytokine levels correlate with clinical parameters in Hodgkin's disease, , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 6 (5): 477–482 (1995)Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG), , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 11 (9): 1105–1114 (2000)Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF, , , , , , , , , and 3 other author(s). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 12 (4): 471–477 (2001)Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG), , , , , , , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 6 (9): 901–910 (1995)